PL3371206T3 - Sposoby wytwarzania postaci fukozylowanej i niefukozylowanej białka - Google Patents
Sposoby wytwarzania postaci fukozylowanej i niefukozylowanej białkaInfo
- Publication number
- PL3371206T3 PL3371206T3 PL16797693T PL16797693T PL3371206T3 PL 3371206 T3 PL3371206 T3 PL 3371206T3 PL 16797693 T PL16797693 T PL 16797693T PL 16797693 T PL16797693 T PL 16797693T PL 3371206 T3 PL3371206 T3 PL 3371206T3
- Authority
- PL
- Poland
- Prior art keywords
- fucosilated
- protein
- manufacturing
- methods
- manufacturing fucosilated
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0646—Natural killers cells [NK], NKT cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0681—Cells of the genital tract; Non-germinal cells from gonads
- C12N5/0682—Cells of the female genital tract, e.g. endometrium; Non-germinal cells from ovaries, e.g. ovarian follicle cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/0004—Oxidoreductases (1.)
- C12N9/0006—Oxidoreductases (1.) acting on CH-OH groups as donors (1.1)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/88—Lyases (4.)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
- C12P21/005—Glycopeptides, glycoproteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y101/00—Oxidoreductases acting on the CH-OH group of donors (1.1)
- C12Y101/01—Oxidoreductases acting on the CH-OH group of donors (1.1) with NAD+ or NADP+ as acceptor (1.1.1)
- C12Y101/01271—GDP-L-fucose synthase (1.1.1.271)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y402/00—Carbon-oxygen lyases (4.2)
- C12Y402/01—Hydro-lyases (4.2.1)
- C12Y402/01047—GDP-mannose 4,6-dehydratase (4.2.1.47), i.e. GMD
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6854—Immunoglobulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
- C12N2510/02—Cells for production
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Physics & Mathematics (AREA)
- Cell Biology (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Food Science & Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Plant Pathology (AREA)
- Reproductive Health (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562249828P | 2015-11-02 | 2015-11-02 | |
| US201662338280P | 2016-05-18 | 2016-05-18 | |
| PCT/US2016/059922 WO2017079165A1 (en) | 2015-11-02 | 2016-11-01 | Methods of making fucosylated and afucosylated forms of a protein |
| EP16797693.5A EP3371206B1 (en) | 2015-11-02 | 2016-11-01 | Methods of making fucosylated and afucosylated forms of a protein |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL3371206T3 true PL3371206T3 (pl) | 2021-09-27 |
Family
ID=57326491
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL16797693T PL3371206T3 (pl) | 2015-11-02 | 2016-11-01 | Sposoby wytwarzania postaci fukozylowanej i niefukozylowanej białka |
Country Status (14)
| Country | Link |
|---|---|
| US (3) | US10975168B2 (pl) |
| EP (2) | EP3925970A1 (pl) |
| JP (1) | JP6983772B2 (pl) |
| KR (2) | KR102793554B1 (pl) |
| CN (2) | CN116731147A (pl) |
| AU (2) | AU2016350732A1 (pl) |
| BR (1) | BR112018007356A2 (pl) |
| CA (1) | CA2999047A1 (pl) |
| ES (1) | ES2875274T3 (pl) |
| IL (1) | IL258161B2 (pl) |
| MX (1) | MX2018004831A (pl) |
| PL (1) | PL3371206T3 (pl) |
| SG (2) | SG11201802773RA (pl) |
| WO (1) | WO2017079165A1 (pl) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2018004831A (es) | 2015-11-02 | 2018-08-01 | Genentech Inc | Metodos para confeccionar formas fucosiladas y afucosiladas de una proteina. |
| MX2018008447A (es) * | 2016-01-06 | 2019-05-30 | Oncobiologics Inc | Modulacion de especies afucosilados en una composicion de anticuerpo monoclonal. |
| CN110945028B (zh) | 2017-07-10 | 2023-09-08 | 国际药物发展生物技术公司 | 用非岩藻糖基化促凋亡抗cd19抗体与抗cd20抗体或化疗剂联合治疗b细胞恶性肿瘤 |
| US12325737B2 (en) * | 2018-03-26 | 2025-06-10 | Amgen Inc. | Total afucosylated glycoforms of antibodies produced in cell culture |
| US20210155710A1 (en) | 2018-06-05 | 2021-05-27 | Amgen Inc. | Modulating antibody dependent cellular phagocytosis |
| US20210317499A1 (en) * | 2018-08-29 | 2021-10-14 | United Biopharma Inc. | Afucosylated antibodies and manufacture thereof |
| WO2020055900A1 (en) | 2018-09-11 | 2020-03-19 | Amgen Inc. | Methods of modulating antibody-dependent cell-mediated cytotoxicity |
| HU231514B1 (hu) | 2018-11-07 | 2024-07-28 | Richter Gedeon Nyrt. | Sejttenyészetben előállított rekombináns glikoprotein glikozilációs mintázatának megváltoztatására szolgáló módszer |
| JP7682797B2 (ja) | 2019-03-20 | 2025-05-26 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | クローディン６二重特異性抗体 |
| WO2020191342A1 (en) | 2019-03-20 | 2020-09-24 | The Regents Of The University Of California | Claudin-6 antibodies and drug conjugates |
| CN114144434A (zh) | 2019-05-06 | 2022-03-04 | 美国安进公司 | 调节抗体效应子功能 |
| CN114450593A (zh) * | 2019-09-26 | 2022-05-06 | 美国安进公司 | 产生抗体组合物的方法 |
| WO2021072244A1 (en) * | 2019-10-11 | 2021-04-15 | Beth Israel Deaconess Medical Center, Inc. | Anti-tn antibodies and uses thereof |
| US20230265192A1 (en) * | 2020-07-02 | 2023-08-24 | Gigagen, Inc. | Anti-ctla-4 binding proteins and methods of use thereof |
| EP4352094A1 (en) | 2021-06-07 | 2024-04-17 | Amgen Inc. | Using fucosidase to control afucosylation level of glycosylated proteins |
| WO2023015027A1 (en) * | 2021-08-06 | 2023-02-09 | Anyadi, Llc | Process for producing personalized cancer immunotherapy |
| KR102890992B1 (ko) * | 2023-01-26 | 2025-12-02 | 팔라디바이오텍 주식회사 | 물질의 세포막 파괴 활성을 확인하는데 사용하기 위한 조성물, 및 그의 용도 |
Family Cites Families (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US30985A (en) | 1860-12-18 | Thomas l | ||
| USRE30985E (en) | 1978-01-01 | 1982-06-29 | Serum-free cell culture media | |
| US4560655A (en) | 1982-12-16 | 1985-12-24 | Immunex Corporation | Serum-free cell culture medium and process for making same |
| US4657866A (en) | 1982-12-21 | 1987-04-14 | Sudhir Kumar | Serum-free, synthetic, completely chemically defined tissue culture media |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4767704A (en) | 1983-10-07 | 1988-08-30 | Columbia University In The City Of New York | Protein-free culture medium |
| GB8516415D0 (en) | 1985-06-28 | 1985-07-31 | Celltech Ltd | Culture of animal cells |
| US4927762A (en) | 1986-04-01 | 1990-05-22 | Cell Enterprises, Inc. | Cell culture medium with antioxidant |
| IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
| US4965195A (en) | 1987-10-26 | 1990-10-23 | Immunex Corp. | Interleukin-7 |
| US4968607A (en) | 1987-11-25 | 1990-11-06 | Immunex Corporation | Interleukin-1 receptors |
| AU632065B2 (en) | 1988-09-23 | 1992-12-17 | Novartis Vaccines And Diagnostics, Inc. | Cell culture medium for enhanced cell growth, culture longevity and product expression |
| WO1990005183A1 (en) | 1988-10-31 | 1990-05-17 | Immunex Corporation | Interleukin-4 receptors |
| AU651596B2 (en) | 1990-06-05 | 1994-07-28 | Immunex Corporation | Type II interleukin-1 receptors |
| US5122469A (en) | 1990-10-03 | 1992-06-16 | Genentech, Inc. | Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins |
| JP4124480B2 (ja) | 1991-06-14 | 2008-07-23 | ジェネンテック・インコーポレーテッド | 免疫グロブリン変異体 |
| US6239328B1 (en) | 1992-10-05 | 2001-05-29 | North Carolina State University | Method for reducing expression variability of transgenes in plant cells |
| US6037525A (en) | 1996-08-01 | 2000-03-14 | North Carolina State University | Method for reducing expression variability of transgenes in plant cells |
| US6245974B1 (en) | 1997-08-06 | 2001-06-12 | North Carolina State University | Matrix attachment regions |
| US6177612B1 (en) | 1998-07-31 | 2001-01-23 | Her Majesty The Queen In Right Of Canada, As Represented By The Department Of Agriculture And Agri-Food Canada | Matrix attachment regions |
| AU762382B2 (en) | 1998-09-29 | 2003-06-26 | Pioneer Hi-Bred International, Inc. | MAR/SAR elements flanking RSYN7-driven construct |
| KR100408844B1 (ko) | 2000-07-29 | 2003-12-06 | 한국산업기술평가원 | 동물세포 발현벡터 |
| US7259010B2 (en) | 2000-12-15 | 2007-08-21 | Pangen Biotech Inc. | Expression vector for animal cell containing nuclear matrix attachment region of interferon beta |
| CA2435972C (en) | 2001-01-26 | 2011-09-13 | University Of Lausanne | Matrix attachment regions and methods for use thereof |
| HUP0600342A3 (en) * | 2001-10-25 | 2011-03-28 | Genentech Inc | Glycoprotein compositions |
| WO2005047512A2 (en) | 2003-11-12 | 2005-05-26 | Shering Corporation | Plasmid system for multigene expression |
| MX2007015107A (es) * | 2005-06-03 | 2008-02-15 | Genentech Inc | Metodo para producir anticuerpos con funcion mejorada. |
| JP4997108B2 (ja) * | 2005-07-22 | 2012-08-08 | 協和発酵キリン株式会社 | 遺伝子組換え抗体組成物 |
| JP5298021B2 (ja) * | 2006-10-12 | 2013-09-25 | ジェネンテック， インコーポレイテッド | リンホトキシン−αに対する抗体 |
| TWI513818B (zh) * | 2009-06-02 | 2015-12-21 | Regeneron Pharma | 岩藻糖基化（ｆｕｃｏｓｙｌａｔｉｏｎ）－缺乏之細胞 |
| AU2010256455A1 (en) * | 2009-06-05 | 2012-01-19 | Momenta Pharmaceuticals, Inc. | Methods of modulating fucosylation of glycoproteins |
| CN109797138A (zh) * | 2011-03-06 | 2019-05-24 | 默克雪兰诺有限公司 | 低岩藻糖细胞系及其应用 |
| WO2013013013A2 (en) * | 2011-07-21 | 2013-01-24 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for producing modified glycoproteins |
| EP3036320B2 (en) * | 2013-08-19 | 2024-04-03 | Biogen MA Inc. | Control of protein glycosylation by culture medium supplementation and cell culture process parameters |
| ES2712303T3 (es) * | 2014-11-15 | 2019-05-10 | Zumutor Biologics Inc | Dominio de unión a ADN del sistema CRISPR para la producción de proteínas no fucosiladas y parcialmente fucosiladas |
| US11267899B2 (en) * | 2015-05-13 | 2022-03-08 | Zumutor Biologics Inc. | Afucosylated protein, cell expressing said protein and associated methods |
| MX2018004831A (es) | 2015-11-02 | 2018-08-01 | Genentech Inc | Metodos para confeccionar formas fucosiladas y afucosiladas de una proteina. |
-
2016
- 2016-11-01 MX MX2018004831A patent/MX2018004831A/es unknown
- 2016-11-01 KR KR1020187009379A patent/KR102793554B1/ko active Active
- 2016-11-01 JP JP2018522671A patent/JP6983772B2/ja active Active
- 2016-11-01 SG SG11201802773RA patent/SG11201802773RA/en unknown
- 2016-11-01 WO PCT/US2016/059922 patent/WO2017079165A1/en not_active Ceased
- 2016-11-01 CA CA2999047A patent/CA2999047A1/en active Pending
- 2016-11-01 AU AU2016350732A patent/AU2016350732A1/en not_active Abandoned
- 2016-11-01 KR KR1020257011036A patent/KR20250051156A/ko active Pending
- 2016-11-01 EP EP21162187.5A patent/EP3925970A1/en active Pending
- 2016-11-01 EP EP16797693.5A patent/EP3371206B1/en active Active
- 2016-11-01 SG SG10202103875WA patent/SG10202103875WA/en unknown
- 2016-11-01 CN CN202310074105.0A patent/CN116731147A/zh active Pending
- 2016-11-01 PL PL16797693T patent/PL3371206T3/pl unknown
- 2016-11-01 CN CN201680077178.3A patent/CN108431026B/zh active Active
- 2016-11-01 ES ES16797693T patent/ES2875274T3/es active Active
- 2016-11-01 BR BR112018007356A patent/BR112018007356A2/pt not_active Application Discontinuation
-
2018
- 2018-03-15 IL IL258161A patent/IL258161B2/en unknown
- 2018-05-01 US US15/968,214 patent/US10975168B2/en active Active
-
2021
- 2021-01-13 US US17/148,456 patent/US11802165B2/en active Active
-
2022
- 2022-04-13 AU AU2022202460A patent/AU2022202460A1/en not_active Abandoned
-
2023
- 2023-09-25 US US18/474,014 patent/US12391769B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| SG11201802773RA (en) | 2018-05-30 |
| US11802165B2 (en) | 2023-10-31 |
| CA2999047A1 (en) | 2017-05-11 |
| AU2022202460A1 (en) | 2022-05-05 |
| EP3925970A1 (en) | 2021-12-22 |
| KR20250051156A (ko) | 2025-04-16 |
| SG10202103875WA (en) | 2021-06-29 |
| IL258161A (en) | 2018-05-31 |
| JP6983772B2 (ja) | 2021-12-17 |
| IL258161B2 (en) | 2023-08-01 |
| KR20180068967A (ko) | 2018-06-22 |
| US20240158536A1 (en) | 2024-05-16 |
| MX2018004831A (es) | 2018-08-01 |
| CN108431026A (zh) | 2018-08-21 |
| IL258161B1 (en) | 2023-04-01 |
| WO2017079165A1 (en) | 2017-05-11 |
| JP2019505164A (ja) | 2019-02-28 |
| US10975168B2 (en) | 2021-04-13 |
| BR112018007356A2 (pt) | 2018-10-23 |
| CN108431026B (zh) | 2023-02-17 |
| EP3371206A1 (en) | 2018-09-12 |
| US12391769B2 (en) | 2025-08-19 |
| ES2875274T3 (es) | 2021-11-10 |
| US20180251572A1 (en) | 2018-09-06 |
| AU2016350732A1 (en) | 2018-04-05 |
| EP3371206B1 (en) | 2021-04-14 |
| KR102793554B1 (ko) | 2025-04-14 |
| CN116731147A (zh) | 2023-09-12 |
| US20210214462A1 (en) | 2021-07-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL304117A (en) | Anti-pvrig antibodies and methods of use | |
| IL282048A (en) | Oxysterols and methods of use thereof | |
| PL3371206T3 (pl) | Sposoby wytwarzania postaci fukozylowanej i niefukozylowanej białka | |
| PL3353210T3 (pl) | Przeciwciała anty-TIGIT i sposoby stosowania | |
| IL255269A (en) | Compositions of obeticholic acid and methods of use | |
| KR20180084817A (ko) | 항-siglec-9 항체 및 이의 이용 방법 | |
| IL251970B (en) | Anti-cd79b antibodies and methods of use | |
| PL3250610T3 (pl) | Przeciwciała anty-FcRn i sposoby ich stosowania | |
| PL3828194T3 (pl) | Oksysterole i sposoby ich stosowania | |
| PL4234581T3 (pl) | Przeciwciała terapeutyczne i ich zastosowania | |
| HUE058755T2 (hu) | Anti-tigit antigénkötõ proteinek és felhasználásuk módszerei | |
| PL3215532T3 (pl) | Przeciwciała anty-TIM3 i sposoby ich zastosowania | |
| PL3265448T3 (pl) | Proleki riluzolu i ich zastosowanie | |
| PL3280441T3 (pl) | Przeciwciała przeciwko sortilinie i sposoby ich stosowania | |
| PL3148579T3 (pl) | Przeciwciała anty-gitr i sposoby ich zastosowania | |
| IL254670A0 (en) | Humanized anti-c1s antibodies and methods of use thereof | |
| DK3368655T3 (da) | Forbedret proteinekspression og fremgangsmåder dertil | |
| PL3498292T3 (pl) | Konstrukty białka uspa2 i ich zastosowania | |
| IL259204B (en) | Compositions and methods of manufacturing protein microparticles | |
| PL3018978T3 (pl) | Sposób konfigurowania i wysterowywania sieci opraw oświetleniowych | |
| IL256322B (en) | Improved formulations of deferasirox and methods of making the same | |
| LT3237432T (lt) | Baltymo gamyba | |
| IL272851A (en) | Methods of using dipivefrin | |
| BR112016025413A2 (pt) | método de fabricação de um inserto e inserto | |
| DK3387019T3 (da) | Relaxin-immunoglobulinfusionsproteiner og anvendelsesfremgangsmåder |